Ridaforolimus

DB06233InvestigationalSmall molecule

Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.

Mechanism: Deforolimus inhibits the mammalian target of rapamycin (mTOR), a serine kinase of the phosphatidylinositol-3-kinase (PI3K) family that regulates protein synthesis, affecting cell growth and proliferation. mTOR is a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways which cancer cells need to proliferate.
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.Curator reviewed
Formula / weight: C₅₃H₈₄NO₁₄P · 990.222 g/mol (avg)
Also known as: Deforolimus
Code names: AP-23573 · MK-8669

Resolves to

Compound

UNII48Z35KB15KCAS572924-54-0ChEMBLCHEMBL2103839ChEBI79700KEGGC15183

Clinical / RWD

ATCL01EG03

Structure

InChIKeyBUROJSBIWGDYCN-GAUTUEMISA-NSMILES

CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O

Targets

P42345MTOR

What you can answer from here — as of May 05, 2022

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

351Drug interactionsStructured to mechanism, not free text

30Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ridaforolimus, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account